Pharma Cash Rolls Into Congress To Defend An Embattled Industry
Congress has a variety of reforms in mind that could roil the drugmaking business and potentially slash prices.
Drug Costs
321 - 340 of 686 Results
-
-
Addiction Clinics Market Pricey, Unproven Treatments To Desperate Patients
An amino acid infusion called NAD is not approved by the FDA to treat addiction. Yet patients with addiction can be desperate enough to try it, at prices as high as $15,000.
-
Readers And Tweeters Take Dialysis Providers To Task: Nowhere But In The USA
Kaiser Health News gives readers a chance to comment on a recent batch of stories.
-
KHN’s ‘What The Health?’: All About Medicare
Before “Medicare for All,” there was just Medicare, the federal program that provides insurance to 60 million Americans. This week, KHN’s Julie Rovner talks to Tricia Neuman of the Kaiser Family Foundation about how Medicare works and whom it serves. Then, Joanne Kenen of Politico, Paige Winfield Cunningham of The Washington Post and Kimberly Leonard of the Washington Examiner join Rovner to talk about some current Medicare issues being debated in Washington, D.C.
-
Shopping Abroad For Cheaper Medication? Here’s What You Need To Know
Americans routinely skirt federal law by crossing into Canada and Mexico or tapping online pharmacies abroad to purchase prescription medications at a fraction of the price they would pay at home. Is it safe? Not necessarily. Here’s some advice.
-
KHN’s ‘What The Health?’: We Answer Your Questions
You asked about drug prices, the “Cadillac tax” on generous insurance plans and why Americans don’t know that most other countries also have combination public-private insurance systems. This week, Anna Edney of Bloomberg News, Alice Miranda Ollstein of Politico and Caitlin Owens of Axios join KHN’s Julie Rovner to answer those questions.
-
KHN’s ‘What The Health?’: Gun Violence And The Politics Of Public Health
The recent tragic mass shootings have refocused efforts to treat gun violence as a public health issue rather than strictly a law enforcement problem. Margot Sanger-Katz of The New York Times, Alice Miranda Ollstein of Politico and Mary Agnes Carey of Kaiser Health News join KHN’s Julie Rovner to discuss this, plus the health implications of the budget deal passed by Congress and signed by President Donald Trump, as well as reaction from Canada to a proposal to allow broader imports of its prescription drugs. Plus, for “extra credit,” the panelists recommend their favorite health stories of the week.
-
Drugmakers Master Rolling Out Their Own Generics To Stifle Competition
Known as “authorized generics,” in-house spinoffs of brand-name drugs quietly undermine the competition.
By Jay Hancock and Sydney Lupkin -
Podcast
KHN’s ‘What The Health?’: Deciphering The Democrats’ Health Debate
Health care was a major topic at the Democratic presidential candidate debates in Detroit on Tuesday and Wednesday, but the focus on plan minutiae may have left viewers more confused than edified. Alice Ollstein of Politico, Kimberly Leonard of the Washington Examiner and Caitlin Owens of Axios join KHN’s Julie Rovner to discuss the points made by the candidates plus a series of Trump administration health initiatives on drug prices and hospital shopping.
-
California Bill Would Fight Deals That Delay Generic Drugs
As California Attorney General Xavier Becerra cracks down on pharmaceutical companies he said paid competitors to delay generic versions of their drugs, he’s also pushing for legislation that would give his department tools to catch more of them. It’s the first of its kind in the nation.
-
Trump Administration ‘Open For Business’ On Drug Imports From Canada
HHS secretary announces a preliminary plan Wednesday to allow Americans to import certain lower-cost drugs from Canada. Manufacturers were quick to criticize the plan, saying it does not guarantee the safety of drugs coming into the country.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don't have to.
-
Klobuchar Says D.C. Has Enough Drug Lobbyists To Double-Team Lawmakers
The drug industry has the biggest lobbying war chest.
-
GOP Senators Distance Themselves From Grassley And Trump’s Efforts To Cut Drug Prices
Even some Republicans who supported a sweeping bipartisan bill to rein in drug costs may not back it in the Senate vote.
-
KHN’s ‘What The Health?’: Cue The Drug Price Debate
Democrats and Republicans on the Senate Finance Committee unveiled their long-awaited proposal to try to rein in prescription drug costs, even as bipartisan leaders of the other Senate committee that oversees health announced it would not bring its drug price bill to the Senate floor until fall. Paige Winfield Cunningham of The Washington Post, Rebecca Adams of CQ Roll Call and Alice Miranda Ollstein of Politico join KHN’s Julie Rovner to discuss this, plus court actions on health issues.
-
A Conservative Group Paints Trump’s Drug-Pricing Experiment As ‘Socialist.’ Is It?
The Americans for Tax Reform commercial takes too broad a brush against an initiative under consideration by the administration that would be part of the president’s promise to curb high drug prices.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don't have to.
-
KHN’s ‘What The Health?’: Biden Doubles Down On Obamacare
Presidential candidate Joe Biden unveiled a health plan intended to provide a more moderate alternative to his competitors’ “Medicare for All” plans. It would build on the Affordable Care Act but would go much further. Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico and Kimberly Leonard of the Washington Examiner join KHN’s Julie Rovner to discuss this, plus Planned Parenthood’s very bad week, the U.S. House vote to repeal the health law’s “Cadillac tax” on generous health plans, and the reduction in deaths from opioids.
-
A ‘No-Brainer’? Calls Grow For Medicare To Cover Anti-Rejection Drugs After Kidney Transplant
Banking on new cost estimates, a bipartisan coalition in Congress is poised to try — once again — to end a three-year limit on coverage for lifesaving medication required to keep the organs functioning.
-
Even When HIV Prevention Drug Is Covered, Other Costs Block Treatment
The U.S. Preventive Services Task Force recommended that people who are at high risk of contracting HIV take PrEP, a preventive treatment. The decision means most health plans will be required to cover the drugs without charging patients. But the recommendation doesn’t apply to the other clinical and lab services people need.